Abstract
Introduction
Epidermolysis bullosa pruriginosa (EBP) is a clinical variant of dystrophic epidermolysis bullosa (DEB), characterized by intense pruritus and hypertrophic, lichenified, prurigo-like papules, plaques, and nodules secondary to scratching. These clinical findings have been attributed to various mutations in the COL7A1 gene. Previous reports have yielded inconsistent findings regarding a possible genotype–phenotype relationship in EBP.
Objective
Our aim was to conduct a systematic review aimed at assessing the genotype–phenotype correlation in EBP.
Methods
A systematic review was conducted using PubMed, Medline, EMBASE, and Cochrane databases for all reports of mutation-verified EBP, published from 1946 to September 2014. Statistical comparison of clinical findings between mutation types was performed using logistic regression analysis.
Results
The review included a total of 28 articles with 74 individuals, which consisted of level 4 non-controlled case series (grade C) and level 5 case reports (grade D). Previous reported mutation types included glycine substitution (GS, 52.7 %), in-frame skipping (IFS, 33.8 %), non-glycine substitution (NGS, 8.1 %), and premature termination codon (PTC, 5.4 %). The most common clinical findings were extremities involvement, linear configuration, and nail dystrophy. In comparison with GS mutation carriers, IFS carriers had a higher likelihood of (1) being male (OR 2.99; p = 0.043; 95 % CI 1.27–11.4) and (2) presenting with blisters (OR 4.10; p = 0.013; 95 % CI 1.34–12.5).
Conclusions
To our knowledge, this study is the first systematic review examining the relationship between mutation type and clinical presentation in EBP. The findings in this review (1) identify common clinical characteristics of EBP that may help in the assessment of patients with possible EBP; and (2) indicate that certain mutation carriers may have a higher likelihood of exhibiting particular phenotypes. In the case of potential diagnostic challenge, assessment for presence of common clinical findings as well as molecular testing may facilitate correct identification and prognostication.
Similar content being viewed by others
References
Fine JD, Eady RA, Bauer EA, Bauer JW, Buckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J Am Acad Dermatol. 2008;58(6):931–50.
Tey HL, Lee AD, Almaani N, McGrath JA, Mills KC, Yosipovitch G. Epidermolysis bullosa pruriginosa masquerading as psychogenic pruritus. Arch Dermatol. 2011;147(8):956–60.
McGrath JA, Schofield OM, Eady RA. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol. 1994;130(5):617–25.
Banky JP, Sheridan AT, Storer EL, Marshman G. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol. 2004;140(7):794–6.
Schumann H, Has C, Kolhase J, Bruckner-Tuderman L. Dystrophic epidermolysis bullosa pruriginosa is not associated with frequent FLG gene mutations. Br J Dermatol. 2008;159(2):464–9.
Broekaert SM, Knauss-Scherwitz E, Biedermann T, et al. Epidermolysis bullosa pruriginosa due to a glycine substitution mutation in the COL7A1-gene. Acta Derm Venereol. 2006;86(6):556–7.
Jones RR. Epidermolysis bullosa. Report of a family and discussion of the dominant dystrophic types. Clin Exp Dermatol. 1979;4(3):303–8.
Dang N, Klingberg S, Marr P, Murrell DF. Review of collagen VII sequence variants found in Australasian patients with dystrophic epidermolysis bullosa reveals nine novel COL7A1 variants. J Dermatol Sci. 2007;46(3):168–78.
Lee JY, Pulkkinen L, Liu HS, Chen YF, Uitto J. A glycine-to-arginine substitution inthe triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa pruriginosa. J Invest Dermatol. 1997;108(6):947–9.
Mellerio JE, Ashton GH, Mohammedi R, Lyon CC, Kirby B, Harman KE, et al. Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol. 1999;112(6):984–7.
Whittock NV, Ashton GH, Mohammedi R, Mellerio JE, Matthew CG, Abbs SJ, et al. Comparative mutation detection screening of the type VII collagen gene (COL7A1) using the protein truncation test, fluorescent chemical cleavage of mismatch, and conformation sensitive gel electrophoresis. J Invest Dermatol. 1999;113(4):673–86.
Murata T, Masunaga T, Shimizu H, Takizawa Y, Ishiko A, Hatta N, et al. Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. Arch Dermatol Res. 2000;292(10):477–81.
Jiang W, Bu D, Yang Y, Zhu X. A novel splice site mutation in collagen type VII gene in a Chinese family with dominant dystrophic epidermolysis bullosa pruriginosa. Acta Derm Venereol. 2002;82(3):187–91.
Nakamura H, Sawamura D, Goto M, Sato-Matsumura KC, LaDuca J, Lee JY, et al. The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familiar clinical heterogeneity in dominant dystrophic epidermolysis bullosa. J Dermatol Sci. 2004;34(3):195–200.
Chuang GS, Martinez-Mir A, Yu HS, Sung FY, Chuang RY, Cserhalmi-Friedman PB, et al. A novel missense mutation in the COL7A1 gene underlies epidermolysis bullosa pruriginosa. Clin Exp Dermatol. 2004;29(3):304–7.
Drera B, Castiglia D, Zoppi N, Gardella R, Tadini G, Floriddia G, et al. Dystrophic epidermolysis bullosa pruriginosa in Italy: clinical and molecular characterization. Clin Genet. 2006;70(4):339–47.
Ee HL, Liu L, Goh CL, McGrath JA. Clinical and molecular dilemmas in the diagnosis of familial epidermolysis bullosa pruriginosa. J Am Acad Dermatol. 2007; 56(5 suppl):S77–S81.
Almaani N, Liu L, Harrison N, Tanaka A, Lai-Cheong J, Mellerio JE, et al. New glycine substitution mutations in type VII collagen underlying epidermolysis bullosa pruriginosa but the phenotype is not explained by a common polymorphism in the matrix metalloproteinase–1 gene promoter. Acta Derm Venereol. 2009;89(1):6–11.
Oxford Centre for Evidence-based Medicine—levels of evidence. University of Oxford, Medical Sciences Division. March 2009. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed 03 Dec 2014.
De Irala J, Navajas RF, del Castillo AS. Abnormally wide confidence intervals in logistic regression: interpretation of statistical program results. Pan Am J Public Health. 1997;1(3):230–4.
Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502–8.
Nagy N, Tanaka A, Techanukul T, McGrath JA. Common IL-31 gene haplotype associated with non-atopic eczema is not implicated in epidermolysis bullosa pruriginosa. Acta Derm Venereol. 2010;90(6):631–2.
Mangold AR, Cole CM, DiCaudo DJ, Pittelkow MR, Sekulic A. Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents. J Am Acad Dermatol. 2014;70(6):e136–7.
Vivehanantha S, Carr RA, McGrath JA, Taibiee SM, Madhogaria S, Ilchyshyn A. Epidermolysis bullosa pruriginosa: a case with prominent histopathologic inflammation. JAMA Dermatol. 2013;149(6):727–31.
Tang MM, Leong KF, Cristina H, Bruckner-Tuderman L. Dystrophic epidermolysis bullosa pruriginosa: the first report of a family in Malaysia. Med J Malaysia. 2013;68(1):81–5.
Fortuna G, Di Lorenzo M, Cepeda-Valdes R, Garcia-Garcia C, Salas-Alanis JC. The largest family of the Americas with dominant dystrophic epidermolysis bullosa pruriginosa: a 18-year longitudinal genotype-phenotype study. J Dermatol Sci. 2013;71(3):217–21.
Yang CS, Lu Y, Farhi A, Nelson-Williams C, Kashgarian M, Glusac EJ, et al. An incompletely penetrant novel mutation in COL7A1 causes epidermolysis bullosa pruriginosa and dominant dystrophic epidermolysis bullosa phenotypes in an extended kindred. Pediatr Dermatol. 2012;29(6):725–31.
Yajima M, Nakano H, Sawamura D, Miyachi Y, Kabashima K. Case of dominant dystrophic epidermolysis bullosa pruriginosa with a c.7868G>A (G2623D) mutation in type VII collagen. J Dermatol. 2012;39(12):1087–8.
Jiang W, Sun TT, Lei PC, Zhu XJ. Genotype-phenotype correlation in Chinese patients with dystrophic epidermolysis bullosa pruriginosa. Acta Derm Venereol. 2012;92(1):50–3.
Brick K, Hand JL, Frankel AS, Siegel DH, Thomas KB, El-Azhary R, et al. Epidermolysis bullosa pruriginosa: further clarification of the phenotype. Pediatr Dermatol. 2012;29(6):732–7.
Pruneddu S, Castiglia D, Floriddia G, Cottoni F, Zambruno G. COL7A1 recessive mutations in two siblings with distinct subtypes of dystrophic epidermolysis bullosa: pruriginosa versus nails only. Dermatology. 2011;222(1):10–4.
Murase K, Kanoh H, Ishii N, Hashimoto T, Nakano H, Sawamura D, et al. Bullous dermolysis of the newborn and dystrophic epidermolysis bullosa pruriginosa within the same family: two phenotypes associated with a COL7A1 mutation. Acta Derm Venereol. 2011;91(6):730–1.
Hayashi M, Kawaguchi M, Hozumi Y, Nakano H, Sawamura D, Suzuki T. Dystrophic epidermolysis bullosa pruriginosa of elderly onset. J Dermatol. 2011;38(2):173–8.
Covaciu C, Grosso F, Pisaneschi E, Zambruno G, Gregersen PA, Sommerlund M, et al. A founder synonymous COL7A1 mutation in three Danish families with dominant dystrophic epidermolysis bullosa pruriginosa identifies exonic regulatory sequences required for exon 87 splicing. Br J Dermatol. 2011;165(3):678–82.
Cole C, Sekulic A, DiCaudo D. Epidermolysis bullosa pruriginosa: novel compound heterozygote splice site mutations. J AM Acad Dermatol. 2011;64(2 Suppl):AB94.
Shi BJ, Feng J. A novel missense mutation in the COL7A1 gene causes epidermolysis bullosa pruriginosa. Clin Exp Dermatol. 2009;34(8):e975–8.
Ren X, Liu JY, Zhai LY, Yao Q, Dai X, Cai Z. A splicing mutation in the COL7A1 gene causes autosomal dominant dystrophic epidermolysis bullosa pruriginosa. Br J Dermatol. 2008;158(3):618–20.
Wang Y, Zhao J, Tu P, Jiang W, Zhu X. A novel missense mutation in COL7A1 in a Chinese pedigree with epidermolysis bullosa pruriginosa. J Dermatol Sci. 2007;46(3):211–3.
Saito M, Masunaga T, Ishiko A. A novel de novo splice-site mutation in the COL7A1 gene in dominant dystrophic epidermolysis bullosa (DDEB): specific exon skipping could be a prognostic factor for DDEB pruriginosa. Clin Exp Dermatol. 2009;34(8):e934–6.
Disclosures
Funding:
No funding was received.
Conflicts of interest
W. Kim, A. Alavi, S. Walsh, S. Kim, and E. Pope declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, W.B., Alavi, A., Walsh, S. et al. Epidermolysis Bullosa Pruriginosa: A Systematic Review Exploring Genotype–Phenotype Correlation. Am J Clin Dermatol 16, 81–87 (2015). https://doi.org/10.1007/s40257-015-0119-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-015-0119-7